Top Industry Leaders in the Insulin Biosimilars Market
Latest Insulin Biosimilars Companies Update:
Eli Lilly and Company (US) launches Rezvoglar (insulin glargine-aglr), its interchangeable biosimilar to Lantus, at a 78% discount to the list price of the originator brand.
Biocon Biosimilar Solutions (India) announces a 106% year-over-year increase in sales for its biosimilar portfolio, attributing the growth to market share gains in the US and EU
Teva Pharmaceutical Industries Ltd. (Israel) files a Biologics License Application (BLA) with the US FDA for its long-acting insulin glargine biosimilar, marking its entry into the US insulin biosimilar market.
Mylan Pharmaceutical Inc. (US) and Sanofi S.A. (France) partner to develop and commercialize two interchangeable biosimilars for Novolog and Levemir, targeting the US insulin market.
The European Medicines Agency (EMA) approves Civica Rx’s Semglee biosimilar (insulin glargine-yfgn) for use in the EU, expanding access to this affordable insulin option.
List of Insulin Biosimilars Key companies in the market
- Sanofi S.A.
- Boehringer Ingelheim
- Eli Lilly & Co.
- Novo Nordisk A/S
- Biocon
- Merck & Co.
- Mylan N.V.
- Sandoz
- Fresenius Kabi
- Amgen